Documentos relacionados

1. [Analysis of characteristics of drug resistance gene mutation in HBV RT region of hepatitis B infected patients].
2. Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.
3. A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.
4. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
5. Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes.
6. Lamivudine therapy for chronic hepatitis B in children: a meta-analysis.
7. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients.
8. Long-term data on entecavir treatment for treatment-naive or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients.
9. [Analysis of risk factors for drug resistant mutations in the reverse transcriptase region in chronic hepatitis B virus-infected patients].
10. Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.